NCT01148862已完成不适用
An In-clinic, Randomized, Cross-Over Study to Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System With Hypoglycemic Induction From Exercise
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 10
- 主要终点
- The Primary Treatment Comparison is the Evaluation of the Duration (Minutes) of Induced Hypoglycemia.
研究概览
简要总结
The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise.
The study will consist of a total of 50 subjects, age 16 through 60 years with Type 1 Diabetes Mellitus.
详细描述
50 subjects with previously diagnosed Type 1 Diabetes Mellitus will be studied. The subject population includes the following subsets: 4 pediatric subjects aged 16 -17 years, 4 young adult subjects age 18-21 years, and 42 adult subjects age 22-60 years at time of enrollment. Results for all subjects will be analyzed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is between the ages of 16 - 60 years old
- •A clinical diagnosis of Type 1 Diabetes Mellitus, as determined by the Investigator, for a minimum of 12 months duration
- •Subject has been on a Medtronic insulin pump for at least 3 months, which includes but is not limited to those on sensor augmented insulin pump therapy
- •Subject has an A1C value between ≥ 7.0% and ≤ 10.0% at time of enrollment; as measured during the screening visit
- •Subject must have a documented stress treadmill test within the last three years of enrollment if the subject had diabetes for >20 years
- •Subject willing to follow protocol and procedures for study.
排除标准
- •Systolic blood pressure on screening visit is >140 Millimeters of Mercury
- •Diastolic blood pressure on screening visit is >90 Millimeters of Mercury
- •Subject has a history of hypoglycemic seizure or hypoglycemic coma within the last two years
- •Subject unable to tolerate tape adhesive in the area of sensor placement;
- •Subject has any active adverse skin condition in the area of sensor placement (i.e. psoriasis, rash, staphylococcus infection) that is not resolved at the time of enrollment
- •Subject is pregnant or plans to become pregnant during the course of the study
- •Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
- •Subject has active Graves disease
- •Subject with renal impairment or creatinine above the normal reference range (of the laboratory that the clinical site is utilizing), as demonstrated by the screening laboratory value
- •Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for hematocrit, as demonstrated by screening laboratory value
- •Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for potassium, as demonstrated by screening laboratory value
- •Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for Thyroid-Stimulating Hormone (TSH), as demonstrated by screening laboratory value
- •Subject is outside of the normal reference range (of the laboratory that the clinical site is utilizing) for free Thyroxine (T4), as demonstrated by screening laboratory value
- •Subject has history of smoking for >5 years
- •Electrocardiogram findings observed during the screening visit, which are deemed by the investigator to represent active ischemia or a condition that would compromise subject safety
- •The stress treadmill (if subject met inclusion criteria #7) results are deemed by the investigator to represent active ischemia or a condition that would compromise subject safety
- •Subject is currently participating in an investigational study (drug or device)
- •Subject is currently on beta blocker medication
- •Subject has taken oral or injectable steroids within the last 30 days
- •Subject is deemed by the Investigator to be unwilling or unable to follow the protocol
- •Subject has a history of diagnosed medical eating disorder
- •Subject has a history of known illicit drug abuse
- •Subject has a history of known abuse with prescription medication
- •Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely per investigator discretion
- •Subject has a history of current alcohol abuse
- •Any other condition including abnormalities found on the screening tests which in the opinion of the Investigator, may preclude him/her from participating in the study
结局指标
主要结局
The Primary Treatment Comparison is the Evaluation of the Duration (Minutes) of Induced Hypoglycemia.
时间窗: approximately 8 hours per induction experiment
Duration (minutes) of induced hypoglycemia (YSI \< 70 mg/dL)
The Primary Treatment Comparison is the Evaluation of the Severity (Milligrams Per Deciliter) of Induced Hypoglycemia.
时间窗: approximately 8 hours per induction experiment
Severity (Milligrams per Deciliter) of induced hypoglycemia (YSI \< 70 Milligrams per Deciliter) is defined as 70 Milligrams per Deciliter minus absolute lowest blood sugar level
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Tandem Predictive Low Glucose Suspend Inpatient Feasibility StudyInsulin PumpDiabetes MellitusType 1 DiabetesNCT02877771Tandem Diabetes Care, Inc.10
已完成
1 期
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 DiabeticsDiabetes Mellitus, Type 2NCT01147861GlaxoSmithKline39
尚未招募
不适用
Effects of LGI Steam Bread on Glycemia Control in T2DM in ChinaDiabete Type 2NCT06512090Shanghai Punan Hospital of Pudong New District144
已完成
不适用
Glycaemic Load and Pre-meal Insulin Doses in Type 1 Diabetes PatientsType 1 DiabetesNCT01978704Federico II University9
已完成
4 期
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)Metabolic SyndromeHypertensionNCT00234858Abbott280